Alpha Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Alpha Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-19,238	Closed	-$1.6M	–	112
2021 Q2	$1.6M	Buy	19,238 +978	+5%	+$77.5K	0.38%	68
2021 Q1	$1.38M	Buy	18,260 +581	+3%	+$47.5K	0.35%	74
2020 Q4	$1.55M	Buy	17,679 +413	+2%	+$32.7K	0.39%	69
2020 Q3	$1.31M	Sell	17,266 -721	-4%	-$72.9K	0.38%	70
2020 Q2	$2.22M	Sell	17,987 -459	-2%	-$45.6K	0.76%	48
2020 Q1	$1.56M	Buy	18,446 +650	+4%	+$56K	0.69%	50
2019 Q4	$1.5M	Sell	17,796 -624	-3%	-$47.1K	0.55%	62
2019 Q3	$1.24M	Buy	18,420 +1,036	+6%	+$79.8K	0.46%	72
2019 Q2	$1.49M	Buy	+17,384	New	+$1.49M	0.56%	60
2016 Q1	–	Sell	-2,175	Closed	-$228K	–	75
2015 Q4	$228K	Sell	2,175 -25	-1%	-$2.61K	0.18%	64
2015 Q3	$232K	Hold	2,200	–	–	0.21%	56
2015 Q2	$301K	Sell	2,200 -3,487	-61%	-$432K	0.23%	61
2015 Q1	$514K	Hold	5,687	–	–	0.36%	57
2014 Q4	$514K	Hold	5,687	–	–	0.36%	57
2014 Q3	$410K	Buy	5,687 +575	+11%	+$37.8K	0.32%	54
2014 Q2	$318K	Buy	5,112 +787	+18%	+$47.5K	0.23%	63
2014 Q1	$295K	Buy	+4,325	New	+$319K	0.23%	64

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alpha Capital Management's BMRN Position: Q3 2021 in Review

Alpha Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 19,238 shares — an estimated $1.6M sold.

Alpha Capital Management first reported a position in BMRN in Q1 2014 and held it in 17 quarters. The position peaked at $2.22M in Q2 2020. 512 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

Alpha Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Alpha Capital Management sold 19,238 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $1.6M.
Alpha Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 17 quarters.
Alpha Capital Management's BioMarin Pharmaceuticals position peaked at $2.22M in Q2 2020.
512 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Alpha Capital Management's 13F filing for Q3 2021, filed 1 Nov 2021.